MetaVia Secures IRB Approval for Higher-Dose Phase 1 Part 3 Obesity Trial of DA-1726

summarizeSummary

MetaVia Inc. announced Institutional Review Board (IRB) approval for its Phase 1 Part 3 clinical trial of DA-1726, a dual GLP-1 and glucagon agonist for obesity, enabling higher-dose studies and data readout in Q4 2026.

check_boxKey Events

• IRB Approval for Phase 1 Part 3 Trial

  The Institutional Review Board (IRB) at Clinical Pharmacology of Miami has approved the Phase 1 Part 3 clinical trial for DA-1726, MetaVia's lead asset for obesity.

• Higher-Dose Titration Studies Initiated

  The trial will evaluate one-step and two-step dose-escalation strategies, reaching target doses of 48 mg and 64 mg, respectively, in 40 obese, healthy adult subjects.

• Key Data Expected Q4 2026

  Initial dosing is planned for April 2026, with results from the 16-week studies on safety, tolerability, pharmacokinetics, and pharmacodynamics anticipated in the fourth quarter of 2026.

• Advancing Best-in-Class Potential

  The company aims to build on previous results, where the 48 mg dose showed approximately 9% weight loss, and further highlight DA-1726's favorable tolerability and potential advantages over existing GLP-1 therapies.

auto_awesomeAnalysis

This Institutional Review Board (IRB) approval is a significant positive development for MetaVia, a clinical-stage biotechnology company, as it allows the advancement of its lead asset, DA-1726, into higher-dose Phase 1 studies for obesity. The drug targets a highly competitive and lucrative market (GLP-1 agonists) and has shown promising early results. Initiating these studies, particularly with higher titration doses up to 64mg, is crucial for optimizing the drug's profile and demonstrating its potential "best-in-class" efficacy and tolerability. The expected data readout in Q4 2026 provides a clear future catalyst for the stock. For a nano-cap company, successful progression of its lead clinical program is paramount for de-risking and future valuation.